ArticleFrontiers in endocrinology2026
Development and validation of a nomogram model for predicting cardiac autonomic neuropathy in patients with diabetes.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetic Cardiac Autonomic Neuropathy (DCAN), a critical yet frequently underdiagnosed microvascular complication, is associated with increased mortality. Standard cardiovascular autonomic reflex tests (CARTs) are complex and time-consuming, hindering their widespread use in routine screening in clinical settings. This study aimed to develop and validate a predictive nomogram for DCAN in patients with diabetes using readily available clinical variables. Methods: We retrospectively analyzed the clinical data of 453 patients with type 1 or type 2 diabetes hospitalized at Shenzhen People's Hospital between February 2022 and December 2025. The dataset was randomly divided into training (70%) and validation (30%) cohorts. Key predictors were identified using a rigorous selection strategy that combined univariate analysis, least absolute shrinkage and selection operator (LASSO) regression, and multivariate logistic regression. Four candidate prediction models (Logistic Regression (LR), Random Forest, Extreme Gradient Boosting (XGBoost), and Light Gradient Boosting Machine (LightGBM) were constructed and evaluated for discrimination, calibration, and clinical utility. The optimal model was visualized as a nomogram and interactive web calculator. Results: The prevalence of DCAN in the study population was 45.0% (204/453). The following seven independent predictors were identified: a history of diabetic retinopathy (DR) or diabetic kidney disease (DKD), diabetes duration, age, heart rate (HR), fasting plasma glucose (FPG), and HbA1c. Among the algorithms tested, the LR model exhibited the most balanced performance in the validation cohort (area under the curve (AUC) = 0.838) with the highest sensitivity (77.0%) and was thus selected as the optimal prediction tool. Consequently, the LR model was transformed into a predictive nomogram. This nomogram demonstrated good calibration and potential clinical utility for individualized risk assessment. Conclusion: We successfully developed and validated a high-sensitivity prediction model for DCAN applicable to type 1 and type 2 diabetes. The developed visual nomogram and interactive web-based tool are cost-effective and user-friendly instruments that can facilitate early risk assessment and personalized clinical management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.